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Abstract: MicroRNAs (miRNAs) are small noncoding RNAs of about 19–25 nt that regulate gene expression posttranscriptionally under
various cellular conditions, including apoptosis. The miRNAs involved in modulation of apoptotic events in T cells are partially known.
However, heterogeneity associated with cell lines makes it difficult to interpret gene expression signatures, especially in cancer-related
cell lines. Treatment of the Jurkat T-cell leukemia cell line with the universal apoptotic drug, camptothecin, resulted in identification of
two Jurkat subpopulations: one that is sensitive to camptothecin and another that is rather intrinsically resistant. We sorted apoptotic
Jurkat cells from nonapoptotic ones prior to profiling miRNAs through deep sequencing. Our data showed that a total of 184 miRNAs
were dysregulated. Interestingly, the apoptotic and nonapoptotic subpopulations exhibited distinct miRNA expression profiles. In
particular, 6 miRNAs were inversely expressed in these two subpopulations. The pyrosequencing results were validated by real-time
qPCR. Altogether, these results suggest that miRNAs modulate apoptotic events in T cells and that cellular heterogeneity requires careful
interpretation of miRNA expression profiles obtained from drug-treated cell lines.
Key words: Apoptosis, microRNAs, Jurkat, deep sequencing

1. Introduction
Apoptosis is programmed cell death triggered by various
stimuli from outside or inside the cell, such as ligation
of cell surface receptors, treatment with cytotoxic drugs,
or irradiation and it results in transcriptionally regulated
activation of a number of regulatory proteins (Blank and
Shiloh, 2007). Apoptosis is characterized by exposure
of phosphatidylserine on the plasma membrane outer
leaflet, membrane blebbing, cellular shrinkage, chromatin
condensation, and fragmentation of nuclear DNA, leading
to formation of apoptotic bodies (Blagosklonny, 2000;
Baumann et al., 2002).
T cells constitute a vital branch of cell-mediated
immunity and homeostasis of the immune response
is sustained through a balance between proliferation
and apoptosis of T cells. A wealth of information has
accumulated over the past two decades about the
transcriptional regulation of genes mediating apoptosis
in T cells. The recent discovery of small RNAs, however,
suggests that posttranscriptional gene regulatory networks
might have prominent effects on modulation of apoptotic
pathways of T cells (Lodish et al., 2008; O’Connell et al.,
* Correspondence: bunyaminakgul@iyte.edu.tr

2010). MicroRNAs (miRNAs), a type of those small RNAs,
are noncoding small RNAs of about 19–25 nucleotides
in length, which are transcribed by RNA polymerase II
(Bartel, 2004, 2009). Followed by nuclear processing by
Drosha and cytoplasmic processing by Dicer, the mature
miRNA strand negatively regulates gene expression by
translational inhibition or destabilization of mRNAs
(Miska, 2005; Lawrie, 2007; Stefani and Slack, 2008). MiR14 and bantam were the first members of miRNAs shown
to modulate apoptotic functions in Drosophila (Brennecke
et al., 2003; Xu et al., 2003). Over the past few years, a clear
link has been established between apoptosis and miRNAs
(Su et al., 2015), particularly in cancer development
(Kumar et al., 2007; Marcucci et al., 2011).
Besides the significance of miRNAs in T-cell functions,
miRNA-mediated T-cell apoptosis has also been associated
with oncogenic miRNAs in leukemogenesis (Calin et al.,
2009; Pekarsky et al., 2009; Chen et al., 2010). In fact,
miRNA profiling studies particularly on cancerous tissues
have clearly shown that each leukemia type (for instance,
CLL vs. ALL) possesses a prominent miRNA expression
signature (Zanette et al., 2007). Additional studies showed
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that these miRNAs regulate the expression of apoptotic or
antiapoptotic mRNAs (Mott et al., 2007; Xiao et al., 2008;
Akao et al., 2009).
Although the use of cell lines has led to the identification
of a number of dysregulated miRNAs involved in
apoptosis and/or leukemogenesis (Li et al., 2013; Yamada
et al., 2014; Zhou et al., 2014; Fan et al., 2016), cellular
heterogeneity associated with cancerous tissues requires
careful interpretation of the data acquired from human
studies. Cellular heterogeneity is also an important issue
that needs to be taken into account while interpreting
the data collected from cell lines. It is well documented
that cells use cellular heterogeneity to function properly
and survive (Benchaouir, 2004; Stockholm et al., 2007;
Walling et al., 2012). Jurkat cells were also reported to be
heterogeneous as sublines from the same clones displayed
different cellular morphologies and growth patterns
(Snow and Judd, 2009). Although miRNA heterogeneity
is known to exist across different cell lines that originate
from the same cancer type (Lu et al., 2015), the potential
for differential miRNA expression across the cells in the
same cell line has not been reported before. To identify
miRNAs that regulate apoptosis in Jurkat cells and also to
test the effect of cellular heterogeneity on drug response
and miRNA expression profiles, we triggered apoptosis
in Jurkat cells with camptothecin, an inhibitor of DNA
topoisomerase I and a potent inducer of apoptosis (Li
and Liu, 2001; Pommier et al., 2003). Following the drug
treatment, we sorted the apoptotic subpopulation (as
defined by Annexin V positivity) from the nonapoptotic
subpopulation by magnetic beads. Deep sequencing of
small RNAs isolated from each subpopulation revealed
that each subpopulation possessed a distinct miRNA
expression signature that might be associated with a
population-specific apoptotic response.
2. Materials and methods
2.1. Cell culture, drug treatment, and transfection
Jurkat human leukemic T cells (American Type Culture
Collection clone E6.1) were maintained in RPMI 1640
(GIBCO) supplemented with 2 mM L-glutamine, 10%
fetal bovine serum (GIBCO), and 100 U penicillin/100
µg streptomycin (Biochrom AG) in an atmosphere of 5%
CO2 at 37 °C. Cells (n = 106) were treated with different
concentrations of camptothecin (Sigma) and incubated at
37 °C and 5% CO2 to determine the dose kinetics. Cells in
both the treatment and control groups were labeled with
PE-conjugated Annexin V and 7-AAD (BD Pharmingen)
and analyzed by flow cytometry (BD FACSArray) to identify
stages of apoptosis. Cells that were Annexin V-positive
but 7-AAD-negative were defined as early apoptotic ones.
Annexin-V-positive cells were then separated by Annexin
V Microbead Kit (Miltenyi Biotech) according to the
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manufacturer’s instructions. Four fractions were obtained
as follows: untreated Annexin-negative (JNN), untreated
Annexin-positive (JNP), treated Annexin-positive (JAP),
and treated Annexin-negative (JAN) cells. Because
sufficient cells could not be obtained from the JNP cells,
they were excluded from the study.
2.2. Total RNA isolation and deep sequencing
Total RNA was isolated with the mirVana miRNA Isolation
Kit (Ambion) according to the manufacturer’s instructions.
Total RNA samples were treated with the TurboDNase
DNA-free Kit (Ambion) to remove traces of genomic
DNA contamination. RNA integrity was determined by a
bioanalyzer (Agilent 2100) using the RNA 6000 Nano Kit
(average RIN: ~9–10).
Three replicates from JNN, JAP, and JAN cells were
mixed in equal amounts and sequenced using the
Illumina Genome Analyzer by Fasteris (Switzerland).
The fragments missing either adaptor were excluded
from further analyses. The adaptor sequences of 15–29
bp inserts were removed prior to the subsequent data
analyses. The Nexalign program (http://genome.gsc.riken.
jp/osc/english/dataresource/) was used to align reads to
rRNA (NCBI, U133169) and hairpin and mature miRNAs
(miRBase, R18) (Vaz et al., 2010). The sequences were
aligned first for exact matches and then the remaining
sequences were used to identify matches with up to three
mismatches as described previously (De Hoon et al., 2010).
The data were deposited in GEO under accession number
GSE35442.
2.3. Real-time qPCR analyses
RNAs smaller than 200 nt were isolated directly from the
cells using the miRVana miRNA Isolation Kit according
to the manufacturer’s instruction (Ambion). cDNA was
prepared from the small RNAs using the RT2 miRNA cDNA
Kit (SA Biosciences). qPCR was performed in duplicates
of three biological replicates (Roche, LightCycler 480). U6
ncRNA was used for normalization.
2.4. Statistical analyses
Student’s t-test was used to statistically analyze the
biological replicates in flow cytometry and qPCR analyses.
P ≤ 0.05 was accepted as statistically significant.
3. Results
3.1. Identification of two Jurkat subpopulations with
different apoptotic properties
We first performed dose-response (0.5–1024 µM) kinetics
to determine the optimal drug treatment conditions for
capturing cells at the apoptotic stage (Annexin V-positive
and 7-AAD-negative). When Jurkat cells were treated with
camptothecin for 4 h, apoptosis was observed in direct
proportion to the dose applied up to 8 µM (Figure 1A).
Percentage of apoptotic cells did not significantly change
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and reached a plateau after 8 µM. Apoptosis was observed
in 41% of the cells in camptothecin-treated group
compared to 5.5% of the control cells (Figure 1A, P < 0.05).
The unresponsiveness of some cells to the drug led us
to hypothesize that Jurkat cells may contain additional
subpopulations, each of which might have a distinct
camptothecin-mediated apoptotic property. Thus, we
increased the concentration of the drug up to 1 mM (128fold in excess of the maximum 8 µM concentration).
Interestingly, over 50% of the camptothecin-treated cells still
remained relatively resistant to the drug treatment despite
over 100-fold camptothecin concentrations, suggesting the
presence of a drug-resistant second subpopulation (Figure
1A). The apparent difference in the apoptotic response
could stem either from an uneven exposure of the cells to
the drug or from intrinsic resistance of a subpopulation
to the drug. To ensure that the differential apoptotic
capacity of two subpopulations is not due to uneven drug
treatment, we sorted the nonapoptotic cells and retreated
them with the drug. To this end, Jurkat cells were first
treated with 8 µM camptothecin for 4 h and the Annexin
V-negative nonapoptotic cells (JAN) were separated from
the apoptotic cells (JAP) using Annexin V-conjugated
magnetic beads (Figures 1B–1E). Flow cytometry analysis
of the sorted cells showed that the sorting efficiency was
as high as 98.4% (purity > 85%, 95% on average) (Figure
1E). Retreatment of the nonapoptotic cells (JAN) with
8 µM camptothecin for 4 h showed that this fraction of
the cells was indeed intrinsically resistant to induction of
apoptosis by camptothecin. In the first round of treatment,
42.4% of the cells underwent apoptosis, while the second
camptothecin treatment triggered apoptosis in only
7.4% of the JAN cells (Figure 2, P < 0.05). We concluded
that there are intrinsic gene expression properties, e.g.,
miRNAs, associated with resistance to the camptothecininduced apoptosis in Jurkat T cells apparently composed
of at least two subpopulations.
To investigate whether each Jurkat subpopulation
possesses a distinct miRNA expression profile, we
compared the miRNA expression patterns in 3 replicates
of each subpopulation. The JNN sample contained the
Annexin V-negative cells, which were not treated with
the drug (negative control), whereas the JAN and JAP
samples contained the Annexin V-negative (intrinsically
camptothecin-resistant)
and -positive (intrinsically
camptothecin-susceptible) cells, respectively, which were
treated with the drug. It should be noted that although the
majority of the camptothecin-treated cells were Annexin
V-positive and 7-AAD-negative prior to sorting, they
shifted to a Annexin V/7-AAD-double positive phenotype
after sorting. We used the Illumina platform (Fasteris,
Switzerland) to quantitatively measure the amounts
of small RNAs in each sample. After the removal of the

adapter sequences, 91.3% of all reads contained 15–29 bp
inserts. Based on the size of the inserts, there appeared
to be two major small RNA populations, one of 22–23
bp and the other 28 bp, each representing miRNAs and
tRNA-derived small RNAs, respectively (Figure 3). The
alignment of the reads to the known RNAs revealed two
striking points with respect to the small RNA content of
each sample: 1) The control JNN cells are rich in miRNA,
which constitutes 60% of small RNAs. The miRNA content
plummets to 26% and 16% in the camptothecin-treated
JAN and JAP samples, respectively. 2) The drug treatment
induces major tRNA fragmentation, constituting up to
45% of all small RNAs (Figure 3; nt 27–29 region). We did
not notice a major difference in the proportion of other
small RNA categories, although there may be differences
in the expression of individual small RNAs.
3.2. Apoptosis is regulated by differential miRNA
expression
The alignment of reads to the known miRNAs in miRBase
(R18) resulted in identification of 184 miRNAs differentially
expressed among the three samples (Table 1). Our list
includes the differentially expressed miRNAs, whose
expression are greater than 10 reads per million (RPM)
in all three samples. Thus, the number of differentially
expressed genes could be greater. Camptothecin treatment
usually suppresses miRNA expression compared to the
control cells (Table 2: 38 induced miRNAs versus 144
downregulated miRNAs in the JAN or JAP samples). We
identified a single miRNA, miR-1246, overexpressed in the
camptothecin-treated JAN and JAP samples. However, a
total of 79 miRNAs were downregulated in response to the
camptothecin treatment. Interestingly, 16 and 30 miRNAs
were down- and upregulated in the drug-resistant JAP
sample, respectively, whereas they were equally expressed
in the drug-sensitive JAP sample. More interestingly, a
total of 6 miRNAs (let-7b-5p, miR-15a-5p, 324-5p, 128,
425, and 720) were reciprocally expressed in the drugsensitive and resistant cells. To validate our findings
from deep sequencing, we randomly chose 7 miRNAs for
validation by real-time qPCR, namely miR-7, 17, 18a, 25,
26a, 93, and 425. As shown in Figure 4, the qPCR results
were quite consistent with the deep-sequencing data.
4. Discussion
The balance between proliferation and apoptosis is
important for the overall cellular homeostasis. Apoptosis
is particularly important in modulating the fate of
immune cells, including T cells. Microarray and deepsequencing studies have been instrumental in identifying
several miRNAs involved in cell proliferation or apoptosis
(Subramanian and Steer, 2010). However, these studies
were mainly conducted with heterogeneous cancerous
tissues in which the apoptotic states of the cells were not
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Figure 1. Dose response and identification of apoptotic cells by flow cytometry. A) Dose kinetics of camptothecin. Jurkat cells
were treated with a range of camptothecin (0.5–1024 µM) for 4 h and the apoptotic cells were determined with Annexin V/7-AAD
labeling. B–E) Enrichment of apoptotic cells with magnetic bead separation. Jurkat cells were treated with 8 µM camptothecin for 4
h and the apoptotic cells were sorted using an Annexin V magnetic bead separation kit. The apoptosis rate of the following samples
was determined by flow cytometry: B) control, untreated cells (JNN); C) camptothecin-treated cells, D) camptothecin-treated and
magnetic bead-sorted Annexin V-negative cells (JAN); E) camptothecin-treated, magnetic bead-sorted Annexin V-positive cells
(JAP). It is important to note that the cells became Annexin V/7-AAD-double positive following the sorting.

synchronized. Thus, we used the Jurkat cell line and the
universal apoptosis inducer camptothecin to identify the
miRNAs involved in apoptosis. The apoptotic cells were
identified by marking the cells in which phosphatidylserine
was exposed to the cell surface, which is readily detected
by Annexin V labeling. Sorting cells based on their
Annexin-V labeling allowed us to obtain the miRNA
expression profile of a purely apoptotic cell population
(Annexin V/7-AAD-double positive).
MiR-14 and bantam were the first miRNAs shown
to have apoptotic function in Drosophila (Brennecke
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et al., 2003; Xu et al., 2003). Studies on various cancer
cells showed a prominent p53-mediated regulation of
miRNAs, particularly the miR-34 family, miR-215 and
192, with proapoptotic capacity (He et al., 2007; Georges
et al., 2008). However, we did not detect any differential
expression of these miRNAs in our study. Let-7 and miR15/16 were also reported to be associated with apoptosis
(Ghodgaonkar et al., 2009). MiR-16-1 and let-7d, -7g, and
-7i were suppressed in the camptothecin-resistant JAN
cells. MiR-16-2 and miR-15a, on the other hand, were
slightly upregulated. These miRNAs were suppressed in
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Figure 2. Two subpopulations of Jurkat cells with different
camptothecin-mediated apoptotic capacity. Following the
magnetic bead separation of camptothecin-treated and magnetic
bead-sorted Annexin V-negative cells (Figure 1D, JAN cells),
these cells were retreated with camptothecin for 4 h. Apoptosis
was measured with Annexin V/7-AAD labeling. 1st CPT: Cells
treated with camptothecin once; 2nd CPT (JAN): sorted cells that
were retreated with camptothecin.

camptothecin-treated Jurkat cells. The miR-17-92 cluster,
which encodes miR-17-3p, -17-5p, -18a, -19a, -20a, -19b,
and 92, is one of the well-established miRNA clusters with
antiapoptotic activity (He et al., 2007; Georges et al., 2008).
We observed nearly 4- to 5-fold downregulation of these
miRNAs in camptothecin-treated Jurkat cells, parallel to the
published results. MiR-125 and -128, which are reported to
be antiapoptotic miRNAs in Jurkat cells (Yamado et al., 2014;
Zhou et al., 2014), are downregulated in the camptothecintreated cells, as expected. MiR-143, which is expressed at an
extremely low level in cancer cell lines compared to normal
tissues, is involved in Fas-mediated apoptosis in Jurkat cells
(Akao et al., 2009). Accordingly, this particular miRNA was
nearly undetectable in Jurkat cells. However, its expression
did not change in response to the camptothecin treatment.
Our study revealed the involvement of additional
miRNAs that may modulate apoptosis in human Jurkat
T cells (Table 1). The most striking dysregulations were
detected in the expression of miR-17*, -128, -140, -142,
-161, -186, -766, and-1268. Although these miRNAs are
dysregulated in camptothecin-treated Jurkat T cells, we
cannot unequivocally state that they are directly involved
in modulating apoptotic pathways. It is possible that they
may be associated with response to drug treatment, such
as drug efflux. Further studies are required to determine
their involvement, if any, in apoptosis and related signaling
pathways.
Although camptothecin is known to be a potent
apoptosis inducer, a portion of the cells were unresponsive

15 16 17 18 19 20 21 22 23 24 25 26 27 28 29
Insert Length (nt)

Figure 3. Small RNA profiles of camptothecin-treated Jurkat
cells. The 15–29 bp fragments were sorted based on their size
and plotted as percentage. JNN: Small RNA population in the
drug-free control cells; JAP: camptothecin-treated and Annexin
V-positive cells; JAN: camptothecin-treated and Annexin
V-negative cells.

to the drug despite over 100-fold increase in the drug
concentration (Figures 1A and 1C). This observation
was consistent with previous reports that there may be
phenotypic and genotypic heterogeneity in clonal cell
populations (Stockholm et al., 2007; Walling and Shepard,
2012). To validate the cellular heterogeneity in the Jurkat
cell line, we sorted the Annexin-V-positive cells (JAP) from
the Annexin-V-negative cells (JAN) following the initial
drug treatment and retreated the Annexin-V-negative,
apoptosis-resistant cells with camptothecin. Although
the inclusion of the Annexin-V-positive fraction of the
untreated control cells (JNP) would provide valuable insight
into the potential role of miRNAs in natural or accidental
death (i.e. drug-independent), the number of these cells
was always insufficient for downstream experiments. Thus,
we focused on the drug-treated samples. Interestingly,
some of the drug-tested cells were intrinsically resistant to
the drug (Figure 1C and Figure 2). To investigate whether
the differential apoptotic response of each subpopulation
is associated with the differential miRNA expression, we
subjected the total RNAs from each subpopulation to deep
sequencing using the untreated cells as control. There were
79 miRNAs commonly downregulated in both populations
(Table 2). Quite interestingly, although 16 and 30 miRNAs
were down- and upregulated in the drug-resistant JAN
sample, respectively, they were equally expressed in the
drug-sensitive JAP sample. More interestingly, a total of
6 miRNAs (let-7b-5p, miR-15a-5p, 324-5p, 128, 425, and
720) were reciprocally expressed in the drug-sensitive JAP
and resistant JAN subpopulations (Table 1). Pending the
direct demonstration of their role in cell-specific response
to drugs, this observation suggests that the miRNA
expression data obtained from drug treatments should be
carefully interpreted if the cells of the desired phenotype
are not sorted from the other cells. The presence of cells
with undesired phenotypes may introduce noise that may
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Table 1. A list of miRNAs deregulated in camptothecin-treated Jurkat cells. The cloning frequency of miRNAs was calculated as reads
per million (RPM) following the removal of the adapter sequences. The miRNAs with a cloning frequency of 10 RPM in all three samples
were used in calculations. The fold of expression is presented in a log ratio. JNN: Drug-free control cells; JAN: Annexin V-negative
fraction of drug-treated cells; JAP: Annexin V-positive fraction of drug-treated cells.
Upregulated in JAN

Suppressed in JAN vs JNN

miRNA

JAN/JNN

JAP/JNN

JAP/JAN

miRNA

JAN/JNN

JAP/JNN

JAP/JAN

hsa-miR-128

4.82

–2.94

–7.75

hsa-miR-19b-3p

–1.63

–4.34

–2.71

hsa-miR-17-3p

7.14

0.51

–6.62

hsa-miR-19a-3p

–1.73

–4.31

–2.59

hsa-miR-720

1.74

–3.42

–5.15

hsa-miR-17-5p

–1.59

–3.87

–2.28

hsa-miR-7-5p

3.53

–0.52

–4.05

hsa-miR-20b-5p

–1.10

–3.23

–2.13

hsa-miR-1268b

3.79

–0.26

–4.05

hsa-miR-210

–1.91

–3.97

–2.06

hsa-miR-1268a

3.77

–0.26

–4.04

hsa-miR-374a-5p

–1.09

–2.93

–1.84

hsa-miR-25-3p

3.49

–0.41

–3.90

hsa-miR-320a

–2.57

–4.29

–1.72

hsa-let-7b-5p

1.60

–2.19

–3.79

hsa-miR-29b-3p

–5.01

–6.44

–1.43

hsa-miR-324-5p

1.87

–1.85

–3.72

hsa-let-7d-5p

–1.95

–3.29

–1.34

hsa-miR-106b-3p

2.76

–0.86

–3.62

hsa-miR-185-5p

–1.27

–2.34

–1.08

hsa-miR-101-3p

2.62

–0.66

–3.28

hsa-miR-484

–1.83

–2.77

–0.94

hsa-miR-221-3p

3.17

–0.07

–3.23

hsa-miR-150-3p

–1.02

–1.86

–0.83

hsa-miR-331-3p

2.85

–0.36

–3.21

hsa-miR-20b-3p

–1.34

–2.14

–0.80

hsa-miR-15a-5p

1.88

–1.09

–2.97

hsa-miR-106a-5p

–2.50

–3.24

–0.74

hsa-miR-28-3p

1.75

–0.95

–2.70

hsa-miR-153

–1.56

–2.22

–0.66

hsa-let-7d-3p

1.52

–0.99

–2.51

hsa-miR-542-5p

–1.77

–2.43

–0.65

hsa-miR-16-2-3p

1.62

–0.68

–2.30

hsa-miR-1301

–2.37

–3.01

–0.64

hsa-miR-21-5p

1.63

–0.63

–2.26

hsa-miR-148a-5p

–1.35

–1.87

–0.53

hsa-miR-3613-5p

2.02

–0.21

–2.23

hsa-miR-454-3p

–1.35

–1.85

–0.49

hsa-miR-181d

1.87

–0.33

–2.20

hsa-miR-26b-5p

–3.17

–3.58

–0.41

hsa-miR-362-5p

2.13

–0.07

–2.20

hsa-miR-181b-3p

–1.20

–1.54

–0.34

hsa-miR-548d-5p

1.66

–0.50

–2.16

hsa-miR-191-5p

–4.24

–4.57

–0.33

hsa-miR-301a-5p

1.54

–0.37

–1.92

hsa-miR-301b

–1.86

–2.17

–0.31

hsa-miR-186-3p

1.68

–0.17

–1.84

hsa-miR-20a-5p

–3.54

–3.83

–0.30

hsa-miR-1307-3p

1.08

–0.63

–1.71

hsa-miR-222-3p

–1.69

–1.93

–0.24

hsa-miR-671-3p

1.07

–0.54

–1.61

hsa-miR-30c-1-3p

–2.58

–2.81

–0.22

hsa-miR-32-3p

1.30

–0.27

–1.57

hsa-miR-590-3p

–1.19

–1.41

–0.21

hsa-miR-378d

1.32

–0.03

–1.35

hsa-miR-183-5p

–1.08

–1.29

–0.21

hsa-miR-589-5p

1.01

–0.30

–1.31

hsa-miR-342-5p

–1.13

–1.30

–0.17

hsa-miR-4677-3p

1.13

–0.16

–1.28

hsa-miR-545-5p

–1.03

–1.19

–0.17

hsa-miR-548w

1.35

0.09

–1.25

hsa-miR-625-3p

–1.34

–1.51

–0.16

hsa-miR-378c

1.14

–0.09

–1.23

hsa-miR-30b-3p

–2.59

–2.71

–0.12

hsa-miR-29b-1-5p

1.06

0.00

–1.06

hsa-miR-146b-5p

–1.84

–1.92

–0.07

hsa-miR-193a-5p

1.75

0.69

–1.06

hsa-miR-4454

–1.13

–1.19

–0.06

hsa-miR-424-3p

1.20

0.21

–0.99

hsa-miR-503

–1.61

–1.65

–0.04

hsa-miR-1246

1.86

2.73

0.87

hsa-miR-99b-5p

–1.13

–1.14

–0.01
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hsa-miR-106a-3p

–1.04

–1.04

0.00

hsa-miR-1285-3p

–1.39

–1.39

0.00
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Table 1. (Continued).
Equal in JAN vs. JNN

hsa-miR-331-5p

–1.78

–1.78

0.00

miRNA

JAN/JNN

JAP/JNN

JAP/JAN

hsa-miR-28-5p

–1.12

–1.08

0.03

hsa-miR-92a-1-5p

–0.87

–4.54

–3.67

hsa-miR-19b-1-5p

–2.85

–2.80

0.05

hsa-miR-26a-5p

–0.35

–3.69

–3.35

hsa-miR-1277-3p

–3.02

–2.97

0.05

hsa-miR-18a-5p

–0.41

–3.62

–3.21

hsa-miR-96-5p

–2.39

–2.34

0.05

hsa-miR-301a-3p

0.86

–2.17

–3.03

hsa-miR-744-3p

–1.24

–1.17

0.07

hsa-miR-125a-5p

0.69

–2.26

–2.94

hsa-miR-29a-3p

–3.01

–2.94

0.07

hsa-miR-18b-5p

0.59

–2.15

–2.74

hsa-miR-532-5p

–1.20

–1.12

0.08

hsa-let-7a-5p

0.33

–2.18

–2.52

hsa-miR-26b-3p

–1.28

–1.19

0.10

hsa-miR-296-3p

–0.01

–2.48

–2.47

hsa-let-7g-3p

–1.98

–1.88

0.11

hsa-miR-27b-3p

0.71

–1.74

–2.45

hsa-miR-130b-3p

–4.70

–4.58

0.12

hsa-miR-148a-3p

–0.59

–2.86

–2.27

hsa-miR-140-3p

–1.46

–1.33

0.13

hsa-miR-374b-5p

0.44

–1.81

–2.26

hsa-miR-16-1-3p

–2.84

–2.69

0.15

hsa-miR-92a-3p

0.53

–1.68

–2.21

hsa-miR-151a-5p

–4.74

–4.55

0.19

hsa-miR-744-5p

0.46

–1.68

–2.14

hsa-miR-424-5p

–4.79

–4.59

0.20

hsa-miR-150-5p

0.61

–1.43

–2.04

hsa-miR-223-5p

–1.71

–1.50

0.21

hsa-miR-106b-5p

–0.40

–2.38

–1.98

hsa-miR-30b-5p

–2.58

–2.34

0.24

hsa-miR-191-3p

–0.03

–1.99

–1.96

hsa-let-7i-3p

–2.75

–2.49

0.25

hsa-miR-223-3p

0.50

–1.42

–1.92

hsa-miR-197-3p

–2.08

–1.80

0.28

hsa-miR-18a-3p

–0.35

–2.11

–1.76

hsa-let-7i-5p

–1.92

–1.62

0.30

hsa-miR-92b-3p

0.20

–1.54

–1.75

hsa-miR-30d-3p

–1.37

–1.07

0.30

hsa-miR-29c-3p

–0.66

–2.41

–1.74

hsa-miR-1277-5p

–2.22

–1.88

0.34

hsa-miR-181a-3p

–0.36

–1.89

–1.52

hsa-miR-194-5p

–2.13

–1.76

0.38

hsa-let-7e-5p

–0.72

–2.24

–1.52

hsa-miR-627

–2.09

–1.72

0.38

hsa-miR-219-1-3p

0.53

–0.93

–1.46

hsa-miR-200c-3p

–2.41

–1.96

0.45

hsa-miR-27a-3p

–0.14

–1.59

–1.45

hsa-miR-500a-5p

–1.05

–0.57

0.48

hsa-let-7c

0.22

–1.21

–1.43

hsa-miR-93-3p

–1.42

–0.90

0.52

hsa-miR-98

–0.21

–1.63

–1.42

hsa-miR-146a-5p

–3.25

–2.72

0.53

hsa-miR-942

0.24

–1.17

–1.41

hsa-miR-320b

–1.52

–0.94

0.57

hsa-miR-7-1-3p

0.12

–1.25

–1.38

hsa-miR-9-3p

–1.39

–0.73

0.66

hsa-let-7f-5p

0.10

–1.19

–1.29

hsa-miR-374a-3p

–2.08

–1.42

0.66

hsa-miR-181a-2-3p

0.31

–0.98

–1.28

hsa-miR-320c

–1.59

–0.88

0.71

hsa-miR-652-3p

0.44

–0.78

–1.22

hsa-miR-450b-5p

–1.78

–1.04

0.74

hsa-miR-548b-5p

0.90

–0.31

–1.21

hsa-miR-320d

–1.04

–0.24

0.79

hsa-miR-9-5p

0.57

–0.61

–1.18

hsa-miR-542-3p

–1.44

–0.62

0.83

hsa-miR-93-5p

0.09

–1.08

–1.17

hsa-miR-629-3p

–1.24

–0.38

0.86

hsa-miR-760

0.81

–0.33

–1.14

hsa-miR-148b-3p

–3.28

–2.36

0.92

hsa-miR-184

0.96

–0.15

–1.12

hsa-miR-340-3p

–1.36

–0.44

0.93

hsa-miR-151a-3p

–0.30

–1.32

–1.01

hsa-miR-339-5p

–1.34

–0.27

1.07

hsa-miR-95

0.01

–1.00

–1.01

hsa-miR-345-5p

–1.41

–0.30

1.11

hsa-miR-152

0.12

–0.88

–1.01

hsa-miR-342-3p

–2.72

–1.60

1.11
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Table 1. (Continued).
hsa-miR-501-3p

–0.40

–1.26

–0.86

hsa-miR-126-3p

–1.96

–0.78

1.18

hsa-miR-27b-5p

–0.29

–1.07

–0.78

hsa-miR-193b-3p

–2.05

–0.82

1.23

hsa-miR-15b-3p

–0.55

–1.33

–0.77

hsa-miR-363-3p

–2.82

–1.55

1.27

hsa-miR-30e-3p

–0.40

–1.13

–0.73

hsa-miR-361-5p

–6.52

–5.24

1.28

hsa-miR-203

–0.36

–1.04

–0.69

hsa-miR-126-5p

–2.77

–1.42

1.36

hsa-miR-340-5p

–0.82

–1.34

–0.52

hsa-miR-769-5p

–3.28

–1.87

1.41

hsa-miR-196a-5p

–0.99

–1.39

–0.40

hsa-miR-140-5p

–6.36

–4.74

1.61

hsa-miR-625-5p

–0.88

–1.19

–0.31

hsa-miR-30c-5p

–4.80

–2.90

1.90

hsa-miR-580

–0.85

–1.13

–0.29

hsa-miR-455-3p

–1.37

0.66

2.03

hsa-miR-454-5p

–0.93

–1.01

–0.08

hsa-let-7g-5p

–6.14

–3.78

2.37

hsa-miR-1292

–1.00

–1.02

–0.02

hsa-miR-186-5p

–5.45

–2.80

2.65

hsa-miR-1248

0.06

1.03

0.97

hsa-miR-24-3p

–3.48

–0.81

2.67

hsa-miR-181a-5p

–0.81

0.31

1.13

hsa-miR-142-5p

–6.58

–3.89

2.70

Table 2. A summary of differentially expressed miRNAs and
qPCR validation. The dysregulated miRNAs from Table 1
are summarized. JNN: Control Jurkat cells not treated with
camptothecin; JAN and JAP: Annexin V-negative and -positive
populations of camptothecin-treated cells, respectively; +:
induced miRNAs; -: suppressed miRNAs; =: equally expressed
miRNAs.
JAN/JNN

JAN/JNN

JAP/JAN

#

-

-

=

57

=

-

-

30

+

=

-

29

-

-

+

12

=

-

=

11

-

-

-

10

-

=

=

9

=

=

-

9

-

=

+

7

+

-

-

5

+

+

=

1

+

=

=

1

-

+

+

1

=

+

=

1

=

=

+

1
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hsa-miR-32-5p

–3.12

–0.11

3.01

hsa-miR-142-3p

–4.60

–1.08

3.52

hsa-miR-766-3p

–4.79

–1.05

3.74

hsa-miR-425-5p

–2.48

1.74

4.22

interfere with the accurate assessment of the phenotypespecific miRNA expression profiles.
We then carried out gene ontology analyses using
DIANA to examine which biological processes could be
affected by the miRNAs inversely expressed in the JAN
and JAP samples (Vlachos et al., 2015). MiR-720 was
shown to originate from a tRNA (Schopman et al., 2010).
Thus, we excluded this miRNA in our gene ontology
analyses. Of the other five miRNAs, let-7b-5p targets
modulate the cell cycle, chronic myeloid leukemia,
p53 signaling, hippo signaling, and thyroid hormone
signaling. MiR-15 targets are involved in the cell cycle,
pathways in cancer, and several signaling pathways such
as p53, TGF-beta, hippo, and thyroid hormone. MiR128 target genes are interesting in that they typically
modulate extracellular matrix organization, focal
adhesion, or proteoglycan in cancer. MiR-324 has binding
sites on mRNAs whose biological functions include
hippo signaling, adherence junction, and miRNAs in
cancer while miR-425 target genes function in N-glycan
biosynthesis, adherence junction, thyroid hormone, and
hippo signaling. From these analyses, it is possible to
state that the target genes of these five miRNAs appear
to modulate common biological processes, such as the
cell cycle, focal adhesion, and several key signaling
pathways, such as p53, hippo, and thyroid hormones.
Interestingly, recent studies demonstrate, for example,
the importance of cell-to-cell variation in p53 expression
in inducing apoptosis (Paek et al., 2016). Further studies
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Figure 4. qPCR validation of differentially expressed miRNAs. cDNA was prepared from a fraction of the total RNAs used in deep
sequencing analysis using the RT2 miRNA cDNA Kit (SA Biosciences). qPCR was performed in duplicates of three biological replicates.
U6 small RNA was used for normalization. ±: Standard deviation. qPCR results are graphed side by side with the deep-sequencing data
for visual comparison.

would be required, however, to directly show whether
these biological processes modulate cellular heterogeneity
through the differentially expressed miRNAs reported in
our study.
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